FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to a method of treating CBS deficiency in an individual, comprising determining a metabolic rate of severity of disease or disease progression in an individual, where the metabolic indicator of disease severity or disease progression is total homocysteine (tHcy), and administering to an individual a therapeutically effective amount of a pharmaceutical composition containing a drug substance containing an isolated cystathionine protein-β-synthase (CBS), and where the individual is a patient with a genetically non-heritable disease associated with high levels of tHcy, or a patient with a non-heritable disease associated with CBS deficiency.
EFFECT: invention provides a method of treating individuals with CBS deficiency and/or high tHcy levels, in which HCU has not been diagnosed or its genetic predisposition has not been detected.
2 cl, 4 dwg, 10 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CANCER TREATMENT USING ANTI-NKG2A AGENTS | 2015 |
|
RU2721271C2 |
| COMBINATION OF MONOCLONAL ANTIBODIES OF OX40 AGONIST AND 4-1BB AGONIST FOR CANCER TREATMENT | 2017 |
|
RU2748949C2 |
| METHOD FOR INCREASING THERAPEUTIC EFFICACY OF FEXAPOTIDE TRIFLUTATE IN LUTS TREATMENT | 2020 |
|
RU2825641C2 |
| COMBINATION OF PD-1 ANTAGONIST AND ERIBULIN FOR TREATING CANCER | 2016 |
|
RU2737216C2 |
| IMPROVEMENT OF CLINICAL PARAMETERS THROUGH FACTOR VIII EXPRESSION | 2019 |
|
RU2799048C2 |
| STABLE FORMULATIONS OF ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 AND RELATED TREATMENT METHODS | 2012 |
|
RU2563346C2 |
| THERAPEUTIC DOSING OF NEUREGULIN OR ITS SUB-SEQUENCE FOR TREATING OR PREVENTING HEART FAILURE | 2019 |
|
RU2719199C1 |
| METHODS, THERAPY AND USE FOR TREATING MALIGNANT GROWTH | 2021 |
|
RU2831425C1 |
| METHODS FOR MODULATING CART-CELLS | 2017 |
|
RU2774232C2 |
| METHODS FOR PREVENTING OR TREATING ALLERGIES BY INTRODUCING AN IL-4R ANTAGONIST | 2017 |
|
RU2777328C2 |
